Another study showed a reduction in multiple myeloma after IL-17 neutralization [114], which triggered the initiation of a clinical trial (NCT03111992) to determine the efficacy of IL-17 neutralization using antibody CJM112. This evidence concerns the gene IL17A and plasma cell myeloma.